Notice of Proposed Sale · 144
IRulya Therapeutics Inc.
IRLANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- IRULYA THERAPEUTICS INC
- Issuer CIK
- 0001662774
- SEC file number
- 001-38890
- Phone
- 4159105717
- Person for whose account securities are to be sold
- Dirk Thye
- Relationships to issuer
- Officer
- Street
- 101 College Street, Suite 210
- City
- New Haven
- State / country code
- CT
- Postal code
- 06510
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| COMMON STOCK | 3,700 | 133,328.85 | 1,017,063 | 10/21/2026 | NASDAQ | MERRILL |
Broker / market maker — proposed row 1, entry 1
- Name
- MERRILL
- Street
- 555 CALIFORNIA ST
- City
- SAN FRANCISCO
- State / country code
- CA
- Postal code
- 94104
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON STOCK | 10/30/2025 | RSU | IRULYA THERAPEUTICS INC | 3,700 | N | 10/30/2025 | CASH |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 10/21/2026
- Signed
- Dirk Thye
Company context
Quince Therapeutics, Inc. is committed to transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of PH-ILD, BOS, and SAPH. A Phase 2a study in PH patients has been completed, a Phase 2 clinical study in BOS patients is ongoing, a Phase 2b study in PH-ILD is ongoing, and a Phase 2 study in SAPH is anticipated to begin in late 2026. By pioneering innovative approaches, the company aims to offer new hope and improved quality of life to patients worldwide.
Current securities
Historical securities (1)
Recent company filings
- 3 filingOct 19, 2026
- 3 filingOct 19, 2026
- Regulation FD DisclosureOct 19, 2026
- SCHEDULE 13G - filed by PERCEPTIVE ADVISORS LLC regarding IRulya Therapeutics Inc.Oct 14, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other EventsOct 9, 2026